Skip to content
2000
Volume 21, Issue 32
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867321666140716092512
2014-10-01
2025-05-12
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867321666140716092512
Loading

  • Article Type:
    Research Article
Keyword(s): Cancer; classification; melanoma; nab-paclitaxel; nanoparticles
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test